...
首页> 外文期刊>Cancer Cell International >Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro
【24h】

Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro

机译:EGFR和Notch联合抑制作用对胶质母细胞瘤细胞活力和胶质母细胞瘤诱导的内皮细胞萌发具有累加抑制作用

获取原文
           

摘要

For Glioblastoma (GBM) patients, a number of anti-neoplastic strategies using specifically targeting drugs have been tested; however, the effects on survival have been limited. One explanation could be treatment resistance due to redundant signaling pathways, which substantiates the need for combination therapies. In GBM, both the epidermal growth factor receptor (EGFR) and the notch signaling pathways are often deregulated and linked to cellular growth, invasion and angiogenesis. Several studies have confirmed cross-talk and co-dependence of these pathways. Therefore, this study aimed at testing a combination treatment strategy using inhibitors targeting the notch and EGFR pathways. For evaluation of cell viability a standard MTT assay was used. Western blotting (WB) and Q-RT-PCR were employed in order to assess the protein- and mRNA expression levels, respectively. In order to determine angiogenic processes, we used an endothelial spheroid sprouting assay. For assessment of secreted VEGF from GBM cells we performed a VEGF-quantikine ELISA. GBM cells were confirmed to express EGFR and Notch and to have the capacity to induce endothelial cell sprouting. Inhibition of EGFR and Notch signaling was achieved using either Iressa (gefitinib) or the gamma-secretase inhibitor DAPT. Our data showed that DAPT combined with Iressa treatment displayed increased inhibitory effect on cell viability and abrogated expression and activation of major pro-survival pathways. Similarly, the combinational treatment significantly increased abrogation of GBM-induced endothelial cell sprouting suggesting reduced GBM angiogenesis. This study finds that simultaneous targeting of notch and EGFR signaling leads to enhanced inhibitory effects on GBM-induced angiogenesis and cell viability, thereby stressing the importance of further evaluation of this targeting approach in a clinical setting.
机译:对于胶质母细胞瘤(GBM)患者,已经测试了多种使用特异性靶向药物的抗肿瘤策略;但是,对生存的影响是有限的。一种解释可能是由于多余的信号通路导致的治疗耐药性,这证实了对联合疗法的需求。在GBM中,表皮生长因子受体(EGFR)和Notch信号通路通常都被解除调节,并与细胞生长,侵袭和血管生成有关。几项研究证实了这些途径的串扰和相互依赖性。因此,本研究旨在测试使用针对刻槽和EGFR途径的抑制剂的联合治疗策略。为了评估细胞活力,使用标准MTT测定法。为了评估蛋白质和mRNA的表达水平,分别使用了蛋白质印迹(WB)和Q-RT-PCR。为了确定血管生成过程,我们使用了内皮球体发芽试验。为了评估GBM细胞分泌的VEGF,我们进行了VEGF-quantikine ELISA。已确认GBM细胞表达EGFR和Notch,并具有诱导内皮细胞发芽的能力。使用易瑞沙(gefitinib)或伽玛分泌酶抑制剂DAPT可达到对EGFR和Notch信号的抑制作用。我们的数据表明DAPT结合易瑞沙治疗对细胞生存力的抑制作用增强,主要生存途径的表达和激活被废止。类似地,联合治疗显着增加了GBM诱导的内皮细胞萌发的废除,表明GBM血管生成减少。这项研究发现,同时靶向刻槽和EGFR信号导致对GBM诱导的血管生成和细胞活力的抑制作用增强,从而强调了在临床环境中进一步评估这种靶向方法的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号